Reason for Erratum {#S1}
==================

In Table [2](#T2){ref-type="table"}, the Median OS values (in months) in the column ≥70 years were changed due to a typesetting error. This error does not change the scientific conclusions of the article in any way. The publisher apologizes for this error and the correct version of Table [2](#T2){ref-type="table"} appears below.

###### 

**Select efficacy outcomes from the Phase III trial of nab-paclitaxel plus carboplatin in NSCLC**.

  Treatment             ITT (41)   ≥70 years (42)   Histology (43)                                                               
  --------------------- ---------- ---------------- ---------------- ------ ------- ------ ------ --------- ----- ------ ------- ------
  *n*                   514                         524              74             82     229              221   292            310
  ORR (%)               33                          25               34             24     41               24    26             25
  Response rate ratio              1.313                                    1.385                 1.680                  1.034   
  *p*-Value                        0.005                                    0.196                 \<0.001                0.808   
  Median PFS (months)   6.3                         5.8              8.0            6.8    5.6              5.7   6.9            6.5
  HR                               0.902                                    0.687                 0.865                  0.933   
  *p*-Value                        0.214                                    0.134                 0.245                  0.532   
  Median OS (months)    12.1                        11.2             19.9           10.4   10.7             9.5   13.1           13.0
  HR                               0.922                                    0.583                 0.890                  0.950   
  *p*-Value                        0.271                                    0.009                 0.284                  0.611   

*HR, hazard ratio; IIT, intent-to-treat; nab-P/C, nab-paclitaxel + carboplatin; NSCC, non-squamous cell carcinoma; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; sb-P/C, solvent-based paclitaxel + carboplatin; SCC, squamous cell carcinoma*.
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